Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2020 Filed Oct 14, 2020 22:58 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantPerformance Share Units · Derivative | 20,243 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026958 · form4.xml · derivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,243 Underlying: Performance Share Units · 20,243 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 20,243 shares will be issued. The actual number of shares to be issued could range from a low of 4,049 at minimum performance to a high of 40,486 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F3 · derivative.exercise_date: Vests on August 3, 2023. F3 · derivative.expiration_date: Vests on August 3, 2023. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:51 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantPerformance Share Units · Derivative | 18,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026954 · form4.xml · derivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,173 Underlying: Performance Share Units · 18,173 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 18,173 shares will be issued. The actual number of shares to be issued could range from a low of 3,635 at minimum performance to a high of 36,346 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F3 · derivative.exercise_date: Vests on August 3, 2023. F3 · derivative.expiration_date: Vests on August 3, 2023. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 22:56 UTC |
Martha GeoffreyDirector · CEO
|
GrantPerformance Share Units · Derivative | 51,758 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026957 · form4.xml · derivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,758 Underlying: Performance Share Units · 51,758 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 51,758 shares will be issued. The actual number of shares to be issued could range from a low of 10,352 at minimum performance to a high of 103,516 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F3 · derivative.exercise_date: Vests on August 3, 2023. F3 · derivative.expiration_date: Vests on August 3, 2023. Read SEC document |
| October 09, 2020 Filed Oct 14, 2020 23:01 UTC |
Salmon SeanEVP & Group President Diabetes
|
GrantPerformance Share Units · Derivative | 11,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-026959 · form4.xml · derivative · entry 1 Salmon Sean · CIK 0001792380 · EVP & Group President Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,042 Underlying: Performance Share Units · 11,042 shares Expires not disclosed F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of Medtronic common stock. F2 · shares: The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 11,042 shares will be issued. The actual number of shares to be issued could range from a low of 2,209 at minimum performance to a high of 22,084 shares at maximum performance. If minimum performance metrics are not met, such PSUs may vest at 0 shares. F3 · derivative.exercise_date: Vests on August 3, 2023. F3 · derivative.expiration_date: Vests on August 3, 2023. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:10 UTC |
ANDERSON RICHARD HDirector
|
PurchaseOrdinary Shares | 4,607 | $108.52 | $499,951.64 |
DisclosureSEC source: 0001127602-20-026756 · form4.xml · nonDerivative · entry 1 ANDERSON RICHARD H · CIK 0001200334 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,673 F1 · price: The price reported is the weighted average price. Shares were purchased in multiple transactions at prices ranging from $108.50 to $108.52. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares purchased at each price. F2 · balance_after: This balance increased by 185 shares due to exempt transactions such as dividend reinvestment. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 797 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · derivative · entry 6 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797 Underlying: Ordinary Shares · 797 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: This option become exercisable on June 29, 2018, subject to New Medtronic's achievement of a pre-specified cash Earnings Per Share Growth Rate for fiscal years 2016 through 2018." Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 19,917 | $0.00 Strike: $62.76 | $0.00 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · derivative · entry 5 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,918 Underlying: Ordinary Shares · 19,917 shares Expires 2024-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: This option to purchase 39,835 New Medtronic ordinary shares for $62.76 per share, which was unvested at the effective time of the Merger, was received in the Merger and represents the conversion of 39,835 Medtronic common stock shares for $62.76 per share. This New Medtronic stock option has the same terms and conditions as the original Medtronic stock option. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 797 | $110.00 | $87,670.00 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · nonDerivative · entry 4 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,325 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionOrdinary Shares | 797 | $62.76 | $50,019.72 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · nonDerivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
SaleOrdinary Shares | 19,917 | $110.00 | $2,190,870.00 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · nonDerivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,325 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 21:12 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
Exercise / conversionOrdinary Shares | 19,917 | $62.76 | $1,249,990.92 |
DisclosureSEC source: 0001127602-20-026757 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 23, 2020 Filed Sep 25, 2020 17:42 UTC |
TEN HOEDT ROBEVP & President EMEA
|
SaleOrdinary Shares | 9,584 | $104.34 | $999,994.56 |
DisclosureSEC source: 0001127602-20-025754 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,476 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 21:40 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
SaleOrdinary Shares | 702 | $107.78 | $75,661.56 |
DisclosureSEC source: 0001127602-20-025235 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,366 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 09, 2020 Filed Sep 11, 2020 18:04 UTC |
TEN HOEDT ROBEVP & President EMEA
|
SaleOrdinary Shares | 9,563 | $105.05 | $1,004,593.15 |
DisclosureSEC source: 0001127602-20-024991 · form4.xml · nonDerivative · entry 1 TEN HOEDT ROB · CIK 0001610036 · EVP & President EMEA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,060 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 39,672 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022906 · form4.xml · derivative · entry 4 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,672 Underlying: Ordinary Shares · 39,672 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022906 · form4.xml · derivative · entry 3 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantStock Option (Right to Buy) · Derivative | 35,894 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022906 · form4.xml · derivative · entry 2 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,894 Underlying: Ordinary Shares · 35,894 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:01 UTC |
Liddicoat John REVP & President of Americas
|
GrantOrdinary Shares | 3,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022906 · form4.xml · nonDerivative · entry 1 Liddicoat John R · CIK 0001752060 · EVP & President of Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,827 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 40,302 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022936 · form4.xml · derivative · entry 4 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,302 Underlying: Ordinary Shares · 40,302 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022936 · form4.xml · derivative · entry 3 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantStock Option (Right to Buy) · Derivative | 68,010 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022936 · form4.xml · derivative · entry 2 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,010 Underlying: Ordinary Shares · 68,010 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:16 UTC |
WHITE ROBERT JOHNEVP & President MITG
|
GrantOrdinary Shares | 7,398 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022936 · form4.xml · nonDerivative · entry 1 WHITE ROBERT JOHN · CIK 0001726709 · EVP & President MITG 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,492 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:08 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 34,005 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022922 · form4.xml · derivative · entry 5 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,005 Underlying: Ordinary Shares · 34,005 shares Expires 2030-08-03 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:08 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022922 · form4.xml · derivative · entry 4 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:08 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 43,451 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022922 · form4.xml · derivative · entry 3 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,451 Underlying: Ordinary Shares · 43,451 shares Expires 2030-08-03 F3 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 17:08 UTC |
Surface Carol ASVP, Chief HR Officer
|
GrantOrdinary Shares | 4,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022922 · form4.xml · nonDerivative · entry 1 Surface Carol A · CIK 0001485966 · SVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,040 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:12 UTC |
Wall Brett A.EVP & Group Pres Restora Thera
|
GrantStock Option (Right to Buy) · Derivative | 23,930 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022929 · form4.xml · derivative · entry 4 Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,930 Underlying: Ordinary Shares · 23,930 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:12 UTC |
Wall Brett A.EVP & Group Pres Restora Thera
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022929 · form4.xml · derivative · entry 3 Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:12 UTC |
Wall Brett A.EVP & Group Pres Restora Thera
|
GrantStock Option (Right to Buy) · Derivative | 60,453 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022929 · form4.xml · derivative · entry 2 Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,453 Underlying: Ordinary Shares · 60,453 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:12 UTC |
Wall Brett A.EVP & Group Pres Restora Thera
|
GrantOrdinary Shares | 6,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022929 · form4.xml · nonDerivative · entry 1 Wall Brett A. · CIK 0001473812 · EVP & Group Pres Restora Thera 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,856 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:52 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 49,118 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022893 · form4.xml · derivative · entry 6 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,118 Underlying: Ordinary Shares · 49,118 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:52 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022893 · form4.xml · derivative · entry 5 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:52 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantStock Option (Right to Buy) · Derivative | 86,901 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022893 · form4.xml · derivative · entry 4 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,901 Underlying: Ordinary Shares · 86,901 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:52 UTC |
COYLE MICHAEL JEVP & Group Pres, Cardiac&Vasc
|
GrantOrdinary Shares | 9,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022893 · form4.xml · nonDerivative · entry 1 COYLE MICHAEL J · CIK 0001233311 · EVP & Group Pres, Cardiac&Vasc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,563 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 36,524 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 4 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,524 Underlying: Ordinary Shares · 36,524 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 3 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantStock Option (Right to Buy) · Derivative | 60,453 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · derivative · entry 2 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,453 Underlying: Ordinary Shares · 60,453 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:57 UTC |
Kuntz RichardSVP & Chief Medical & Science
|
GrantOrdinary Shares | 6,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022899 · form4.xml · nonDerivative · entry 1 Kuntz Richard · CIK 0001341125 · SVP & Chief Medical & Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,001 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:55 UTC |
ISHRAK OMARDirector · Executive Chairman
|
GrantStock Option (Right to Buy) · Derivative | 159,318 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022896 · form4.xml · derivative · entry 1 ISHRAK OMAR · CIK 0001523102 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,318 Underlying: Ordinary Shares · 159,318 shares Expires 2030-08-03 F1 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:05 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,378 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022914 · form4.xml · derivative · entry 7 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,378 Underlying: Ordinary Shares · 50,378 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:05 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022914 · form4.xml · derivative · entry 6 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:05 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 83,123 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022914 · form4.xml · derivative · entry 5 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,123 Underlying: Ordinary Shares · 83,123 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:05 UTC |
PARKHILL KAREN LEVP & Chief Financial Officer
|
GrantOrdinary Shares | 9,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022914 · form4.xml · nonDerivative · entry 1 PARKHILL KAREN L · CIK 0001527660 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,068 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 39,043 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022903 · form4.xml · derivative · entry 4 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,043 Underlying: Ordinary Shares · 39,043 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 1,575 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022903 · form4.xml · derivative · entry 3 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,575 Underlying: Ordinary Shares · 1,575 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantStock Option (Right to Buy) · Derivative | 74,622 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022903 · form4.xml · derivative · entry 2 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,622 Underlying: Ordinary Shares · 74,622 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 20:59 UTC |
Lerman Bradley ESVP General Counsel & Corp Sec
|
GrantOrdinary Shares | 8,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022903 · form4.xml · nonDerivative · entry 1 Lerman Bradley E · CIK 0001559405 · SVP General Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,325 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:03 UTC |
Martha GeoffreyDirector · CEO
|
GrantStock Option (Right to Buy) · Derivative | 71,158 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022910 · form4.xml · derivative · entry 3 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,158 Underlying: Ordinary Shares · 71,158 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:03 UTC |
Martha GeoffreyDirector · CEO
|
GrantStock Option (Right to Buy) · Derivative | 212,529 | $0.00 Strike: $97.33 | $0.00 |
DisclosureSEC source: 0001127602-20-022910 · form4.xml · derivative · entry 2 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,529 Underlying: Ordinary Shares · 212,529 shares Expires 2030-08-03 F2 · derivative.exercise_date: These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:03 UTC |
Martha GeoffreyDirector · CEO
|
GrantOrdinary Shares | 23,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022910 · form4.xml · nonDerivative · entry 1 Martha Geoffrey · CIK 0001560409 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,094 F1 · kind: The restrictions on these restricted stock units shall lapse 100% on the third anniversary of the Grant Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.